BOULDER, Colo., Oct. 5 /PRNewswire-FirstCall/ -- Array BioPharma Inc.
(Nasdaq: ARRY) today announced the appointment of Ronald B. Franklin, Ph.D.,
D.A.B.T., to the newly created position of Senior Director of Drug Metabolism,
effective September 27, 2004. Dr. Franklin will oversee Array's Drug
Metabolism group and will report to the company's President and Chief
Scientific Officer, Kevin Koch, Ph.D.
"We are delighted to have someone of Ron's caliber and experience join our
team," said Dr. Koch. "Ron's expertise in the development of innovative ADMET
strategies for the identification of novel, safe and effective therapeutic
agents will be critical as we grow our pipeline of proprietary drug candidates
and expand our research collaborations."
Before joining Array, Dr. Franklin spent six years with Merck and Co. Inc.
at the Rahway, New Jersey site, most recently serving as a Director of
Discovery and Development Research in Preclinical Drug Metabolism. In
addition, he supervised the Quantitative and Qualitative Analysis (LC-MS and
LC-MS/MS) and the Animal Biology groups, the latter being responsible for in
vivo and in vitro techniques for pharmacokinetic studies as well as procedures
that included biliary-cannulation studies and intestinal loop preparations.
In addition, he directed the submission of drug metabolism portions of all
IMPD, CIB, IND and NDA applications stemming from the Rahway site. Prior to
joining Merck, Dr. Franklin worked for three years at Amgen in the Department
for Drug Metabolism and Spectroscopy and 14 years at Eli Lilly and Company, in
the Department of Drug Disposition. He is the author or co-author of over 130
scientific articles and abstracts. Dr. Franklin received a Ph.D. in
Biochemistry from St. Mary's Hospital Medical School, University of London and
a Bachelor of Pharmacy from The London School of Pharmacy, University of
About Array BioPharma:
Array BioPharma is a biopharmaceutical company focused on the discovery,
development and commercialization of orally active drugs to address
significant unmet medical needs. Our proprietary drug development pipeline is
primarily focused on the treatment of cancer and inflammatory disease and
includes several small molecule drug candidates that are designed to regulate
targets in therapeutically important biologic pathways. In addition, leading
pharmaceutical and biotechnology companies access our drug discovery
technologies and expertise through collaborations to design, create, optimize
and evaluate drug candidates across a broad range of therapeutic areas. For
more information on Array, please go to www.arraybiopharma.com.
Array BioPharma Forward-Looking Statement:
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 that involve
significant risks and uncertainties, including those discussed in our annual
report filed on form 10-K for the year ended June 30, 2004, and in other
reports filed by Array with the Securities and Exchange Commission. Because
these statements reflect our current expectations concerning future events,
our actual results could differ materially from those anticipated in these
forward-looking statements as a result of many factors. These factors
include, but are not limited to, our ability to achieve and maintain
profitability, the extent to which the pharmaceutical and biotechnology
industries are willing to collaborate with and fund third parties to
in-license drug candidates for their product pipelines and on their drug
discovery activities, the ability of our collaborators and of Array to meet
drug discovery objectives tied to milestones and royalties, our ability to
continue to fund and successfully progress internal research efforts and to
create effective, commercially viable drugs, and our ability to attract and
retain experienced scientists and management. We are providing this
information as of October 5, 2004. We undertake no duty to update any
forward-looking statements to reflect the occurrence of events or
circumstances after the date of such statements or of anticipated or
unanticipated events that alter any assumptions underlying such statements.
SOURCE Array BioPharma Inc.
Tricia Haugeto of Array BioPharma Inc.
/Web site: http://www.arraybiopharma.com /
10/05/2004 09:00 EDT http://www.prnewswire.com